Heterocyclic compound
AssigneeTakeda Pharmaceutical Company Limited
InventorsEiji KIMURA, Yuhei MIYANOHANA, Masaki OGINO, Yuta TANAKA, Makoto FUSHIMI, Tomohiro OKAWA, Yuki HANYA, Tatsuki KOIKE
Life of this patent
Estimating the term…
Abstract
Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.
Claims18
A compound represented by the formula (I):
- wherein
- ring A is an optionally further substituted ring;
- R1 is a hydrogen atom or a substituent;
- R2 and R3 are each independently a hydrogen atom, an optionally substituted C1-6 alkyl group or an optionally substituted C3 cycloalkyl group;
- Xa is CRa or N;
- Xb is CRb or N;
- Xc is CRc or N;
- Xd is CRd or N;
- Xe is CRe or N;
- and
- Ra, Rb, Rc, Rd and Re are each independently a hydrogen atom or a substituent
- (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide)
- or a salt thereof.
2-(Imidazo[1,2-a]pyridin-5-yl)-N-(4-(trifluoromethyl)phenyl)acetamide or a salt thereof.
2-(Imidazo[1,2-a]pyridin-5-yl)-N-(4-methoxyphenyl)acetamide or a salt thereof.
N-(3-fluoro-4-methoxyphenyl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide or a salt thereof.
(canceled)
(canceled)
Dependencies are inferred from the claim text.